Chronic Wounds & Ulcers stem cell therapy — your questions answered (2026)

About stem cell therapy for Chronic Wounds & Ulcers

Chronic wounds—including diabetic foot ulcers, pressure injuries and vascular ulcers—may fail to close because of impaired perfusion, infection, pressure, metabolic disease and disrupted inflammatory and repair processes. Cells and extracellular vesicles are being studied for proposed effects on immune signalling, angiogenesis, fibroblasts and extracellular matrix in preclinical models. Those mechanisms have not established durable closure or limb salvage in people. Diagnosis and treatment of infection, ischaemia, pressure and the underlying disease remain essential. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Chronic Wounds & Ulcers

Chronic-wound studies of cells and extracellular vesicles vary by wound cause, vascular status, infection, product, delivery, comparator and definition of closure. Treated-cohort percentages and historical controls cannot establish comparative efficacy. Wound-area reduction is not equivalent to durable complete closure, limb salvage or fewer infections. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational wound cell or exosome procedures can involve separate charges for repeated applications, imaging, debridement, dressings, vascular assessment, monitoring, travel and treatment of complications. Prices do not indicate regulatory approval, closure or limb-salvage benefit. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Urgent infection, ischaemia, pressure relief and guideline-directed wound care must not be delayed.

Can stem cells heal chronic wounds?

Cell therapy for Chronic Wounds & Ulcers may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Diabetic-foot ulcers — does it help?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How is it applied?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Chronic Wounds & Ulcers programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Chronic Wounds & Ulcers (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Chronic Wounds & Ulcers overview · Chronic Wounds & Ulcers cost →